Novo Nordisk promotes new GLP-1 receptor agonist to fight diabetes, obesity - KBR
4/28/2022 12:00:00 AM3 yearsago
by Kim Yun-mi
by Kim Yun-mi
Novo Nordisk is seeking to replace the existing glucagon-like peptide-1 (GLP-1) receptor agonist (RA) with a second-generation drug, semaglutide, to fight diabetes and obesity in Korea.On Thursday, the Ministry of Food and Drug Safety authorized the use of No…
Novo Nordisk is seeking to replace the existing glucagon-like peptide-1 (GLP-1) receptor agonist (RA) with a second-generation drug, semaglutide, to fight diabetes and obesity in Korea. On Thursday,… [+1630 chars]
full article...